반응식
[Cl:1][CH2:2][CH2:3][C:4]1[CH:9]=[CH:8][C:7]([N:10]([CH2:14][CH2:15][CH3:16])[C:11](=[O:13])[CH3:12])=[C:6]([CH3:17])[CH:5]=1.Cl.[N:19]1([C:25]2[C:33]3[C:28](=[CH:29][CH:30]=[CH:31][CH:32]=3)[NH:27][N:26]=2)[CH2:24][CH2:23][NH:22][CH2:21][CH2:20]1>>[ClH:1].[NH:27]1[C:28]2[C:33](=[CH:32][CH:31]=[CH:30][CH:29]=2)[C:25]([N:19]2[CH2:20][CH2:21][N:22]([CH2:2][CH2:3][C:4]3[CH:9]=[CH:8][C:7]([N:10]([CH2:14][CH2:15][CH3:16])[C:11](=[O:13])[CH3:12])=[C:6]([CH3:17])[CH:5]=3)[CH2:23][CH2:24]2)=[N:26]1참가 물질
실험 절차
N-[4-(2-Chloro-ethyl)-2-methyl-phenyl]-N-propyl-acetamide (0.090 g, 0.355 mmole) was reacted with 3-piperazin-1-yl-1H-indazole hydrochloride (0.127 g, 0.532 mmol) according to the method outlined in Example 501. The titled product was precipitated as its hydrochloride salt from dioxane/HCl(gas) treatment (0.030 g, 0.071 mmol). Yield=20%. 100% purity at 254 nm; LCMS (APCI): 437.3 [M+H]+, 1H NMR (400 MHz, DMSO-d6) δ 12.19 (s, 1H), 10.50 (s, 1H), 7.79 (d, J=8.55 Hz, 1H), 7.37 (d, J=8.55 Hz, 1H), 7.32–7.26 (m, 2H), 7.21–7.12 (m, 2H), 6.99 (t, J=7.48 Hz, 1H), 3.97 (bd, J=8.70 Hz, 2H), 3.87–3.77 (m, 1H), 3.65 (bd, J=7.25 Hz, 2H), 3.39 (bs, DMSO-H2O), 3.31–3.21 (m, 6H), 3.10–2.92 (m, 3H), 2.14 (s, 3H), 1.58 (s, 3H), 1.39 (sextet, J=7.38 Hz, 2H), 0.79 (t, 7.38 Hz, 3H).
후처리
- customThe titled product was precipitated as its hydrochloride salt from dioxane/HCl(gas) treatment (0.030 g, 0.071 mmol)
출처 및 근거
- ORD 기록
- ord-55e4b1c3170640c6a5ce1c2e7a658f31
- 출처 데이터셋
- uspto-grants-2006_09
- 특허 번호
- US07101886B2
연결된 노트
불러오는 중…